BioMedNewsBreaks

ThursdayAug 13, 2026 12:07 pm

BioMedNewsBreaks — Earth Science Tech, Inc. (OTC: ETST) Acquires Meduvo, Expands Pharmacy Network to 34 U.S. Jurisdictions

Earth Science Tech (OTC: ETST) announced the acquisition of Meduvo LLC, a compounding pharmacy based in La Verne, California, establishing a West Coast operational hub and expanding the company’s network to 34 U.S. jurisdictions. Meduvo currently operates from a 2,000-square-foot facility and compounds and dispenses non-sterile medications. ETST is initiating facility upgrades designed to meet sterility requirements, with management targeting full regulatory certification for sterile compounding by the end of 2028. The company said regulatory approvals are pending in additional states as it pursues nationwide coverage. To view the full press release, visit https://ibn.fm/dvo4H About Earth Science Tech, Inc. (ETST) Earth Science Tech, Inc. operates as a diversified holding company focused on the health and wellness sector.…

Continue Reading

ThursdayAug 13, 2026 9:50 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO to Present at 2026 Georgia Life Sciences Summit

Nutriband (NASDAQ: NTRB) announced that CEO and Co-Founder Gareth Sheridan will present as part of the CEO Spotlight event at the 2026 Georgia Life Sciences Summit on Aug. 26. The summit, scheduled for Aug. 25-26 at the Sandy Springs Performing Arts Centre in Sandy Springs, Georgia, brings together leaders across biotechnology, medical technology, research, manufacturing and investment. Nutriband is developing AVERSA (TM), its abuse-deterrent transdermal technology designed to incorporate aversive agents into patches to help prevent abuse, diversion, misuse and accidental exposure involving drugs with abuse potential. To view the full press release, visit https://ibn.fm/Un3ax About Nutriband Inc. We are primarily…

Continue Reading

WednesdayAug 12, 2026 12:02 pm

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Reports Strong Correlation for Finger-Prick Nu.Q NETs Prototype in Sepsis Patients 

VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced that results using its lateral flow finger-prick prototype were highly correlated with results from its established automated Nu.Q NETs test in critically ill sepsis patients, supporting the potential expansion of nucleosome testing beyond centralized laboratories. The company said the lateral flow test could enable rapid identification of high-risk patients in emergency rooms or at the bedside, with testing showing a Spearman correlation of 0.85 and Pearson correlation of 0.881 compared with its CE-marked laboratory assay. The study, part of the SUMMIT program, evaluated capillary blood and plasma samples from intensive care patients and demonstrated significant correlation between…

Continue Reading

TuesdayAug 11, 2026 2:57 pm

BioMedNewsBreaks — Nano-X Imaging Ltd. (NASDAQ: NNOX) Optimizes Nanox.AI Medical Imaging Framework for Intel Core Ultra Processors 

Nano-X Imaging Ltd. (NASDAQ: NNOX) announced that subsidiary Nanox AI Ltd. has optimized its medical imaging AI application framework for Intel Core Ultra processors using Intel OpenVINO toolkit. The framework is designed to enable healthcare facilities to evaluate and deploy CT imaging AI applications on on-premise edge devices while keeping imaging data within their own infrastructure. Nanox.AI solutions analyze routine CT scans to help identify findings correlated with chronic conditions involving cardiac, liver and bone health. The optimized framework successfully ran inference on Intel Core Ultra-class hardware using OpenVINO, demonstrating its suitability for on-premise medical imaging AI processing. Nanox.AI said the approach can bring AI-enabled imaging insights closer to the point of care, while local edge inference…

Continue Reading

TuesdayAug 11, 2026 1:35 pm

BioMedNewsBreaks — AOM Capital Completes $5.1 Million Financing for Therapeutics Company Acquisition 

AOM Capital announced the completion of a $5.1 million financing for a therapeutics company in connection with its acquisition of a pharmaceutical drug asset. The private investment and specialty bridge lending firm structured the financing around the specific requirements of the transaction, providing the capital needed to support the acquisition. AOM Capital said the transaction expands its activity in private credit, acquisition financing and special situations, with the firm focused on providing flexible capital for acquisitions, bridge transactions, growth initiatives and other complex or time-sensitive opportunities. To view the full press release, visit https://ibn.fm/imbdB About AOM Capital AOM Capital is a private investment and specialty bridge…

Continue Reading

MondayAug 10, 2026 9:10 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that the U.S. Food and Drug Administration has approved its Investigational New Drug (“IND”) application for Lucid-MS (Lucid-21-302), clearing the company to advance the patented, first-in-class multiple sclerosis candidate into Phase 2 clinical development. The planned randomized, double-blind, placebo-controlled study will evaluate efficacy, safety and tolerability in people with MS using clinical and radiological measures. Trial start-up activities, including site selection, are underway, with patient enrollment and drug administration expected to begin as quickly as possible. Lucid-MS…

Continue Reading

MondayAug 10, 2026 9:00 am

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q2 Revenue of $13.5 Million as TONMYA Sales Reach $11 Million

Tonix Pharmaceuticals (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, up from $2 million in the year-ago period, driven by approximately $11 million in net sales of TONMYA. The fibromyalgia treatment recorded 12,592 total prescriptions during the quarter, up 100% sequentially, while new patient prescriptions increased 36% and refills rose 207%. TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare and Medicaid channels, with coverage expected to reach approximately 145 million lives when a managed Medicare agreement takes effect Jan. 1, 2027. Tonix also continued advancing its clinical pipeline, enrolling the first…

Continue Reading

FridayAug 07, 2026 2:59 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory and commercial milestones amid growing interest in regenerative orthopedic solutions. GelrinC is an off-the-shelf, cell-free implant designed for a streamlined, single-step procedure that supports cartilage regeneration without the cell harvesting and laboratory processing required by some alternative approaches. Regentis is continuing enrollment in its U.S. clinical study, preparing for a potential FDA Premarket Approval submission, expanding commercialization efforts in Europe following CE Mark approval, and optimizing manufacturing for scalability and consistency. To view the full article, visit https://ibn.fm/mVCsB About Regentis Biomaterials Ltd. Regentis Biomaterials is a…

Continue Reading

FridayAug 07, 2026 2:16 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Two-Pronged Approach to Neurological Health

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, is developing a two-pronged strategy addressing neurological health through its investigational multiple sclerosis therapy Lucid-MS and its proprietary dietary supplement unbuzzd. Lucid-MS is designed to target PAD2, an enzyme associated with myelin degradation, with the goal of protecting and potentially restoring the myelin sheath rather than primarily modulating the immune system. The company submitted an IND application to the FDA for a Phase 2 trial and is supporting development through an imaging collaboration…

Continue Reading

FridayAug 07, 2026 1:21 pm

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Builds Strategic Position in Antibody Therapeutics Market

VERAXA Biotech (NASDAQ: VRXA) is developing next-generation antibody therapeutics across antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), two areas that continue to attract significant pharmaceutical investment. A recent article highlights major transactions to illustrate how differentiated antibody-engineering platforms can attract substantial financial commitments even before clinical development reaches advanced stages. VERAXA’s proprietary BiTAC platform supports a pipeline that includes bispecific ADCs, T-cell engagers and engineered antibody formats, potentially creating opportunities for future platform partnerships, licensing agreements or asset-level transactions. To view the full article, visit https://ibn.fm/sMjlp About VERAXA Biotech AG VERAXA is building a premier engine for the discovery and development of…

Continue Reading